Change in coronary heart disease hospitalization after chronic disease management: a programme policy in China

Jingmin Zhu1, Wei Wang2, Jun Wang3

  • 1Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London WC1E 7HB, United Kingdom.

Health Policy and Planning
|November 24, 2022
PubMed

Insights

China's new chronic disease management (CDM) program significantly cut coronary heart disease (CHD) hospitalization costs and length of stay. This integrated approach reduced medical expenses and bed days, easing financial burdens.

Area of Science:

  • Public Health Policy
  • Health Services Research
  • Cardiovascular Disease Management

Background:

  • Coronary heart disease (CHD) poses a significant public health challenge.
  • Effective management strategies are crucial for mitigating healthcare costs and patient burden.
  • China's 13th Five-Year period (2016-2020) focused on improving chronic disease care.

Purpose of the Study:

  • To evaluate the impact of a novel county-scale chronic disease management (CDM) program on CHD hospitalization.
  • To assess changes in direct medical costs and length of stay for CHD patients post-CDM implementation.
  • To determine the effectiveness of integrated care models in managing chronic conditions.

Main Methods:

  • Retrospective analysis of 6111 CHD inpatient records from January 2017 to December 2020.
  • Utilized univariate and multivariate regression analyses to assess hospitalization costs and length of stay.
  • Examined data from a secondary hospital following the March 2019 implementation of the CDM program.

Main Results:

  • The CDM program implementation led to an approximate 23% reduction in direct medical costs (1956.12 Yuan mean reduction).
  • Hospitalization length of stay for CHD patients decreased by approximately 11.5% (nearly 1 day mean reduction).
  • A sustained decreasing trend in medical costs over time was observed, correlating with CDM.

Conclusions:

  • The county-scale CDM program is an effective strategy for reducing the financial and medical burden of CHD hospitalizations.
  • Integrated care involving hospitals and primary care institutes improves chronic disease management outcomes.
  • CDM demonstrates potential for significant cost savings and improved resource utilization in cardiovascular care.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
26
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37